Aytu BioPharma (Aytu BioPharma) Pre-Tax Income : $-17.17 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Aytu BioPharma Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Aytu BioPharma's pretax income for the three months ended in Dec. 2023 was $0.61 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-17.17 Mil. Aytu BioPharma's pretax margin was 2.65%.

During the past 13 years, Aytu BioPharma's highest Pretax Margin was -15.88%. The lowest was -10833.90%. And the median was -324.51%.

Aytu BioPharma Pre-Tax Income Historical Data

The historical data trend for Aytu BioPharma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Pre-Tax Income Chart

Aytu BioPharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Pre-Tax Income

Get a 7-Day Free Trial

-27.13

-13.62

-58.03

-108.89

-17.05

Aytu BioPharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-6.69	-7.20	-2.46	-8.12	0.61

Competitive Comparison of Aytu BioPharma's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aytu BioPharma's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Pre-Tax Income falls into.

Aytu BioPharma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Aytu BioPharma's Pretax Income for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-12.329	+	-4.722	+	0	+	0	+	3.5527136788005E-15
	=	-17.05

Aytu BioPharma's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	2.364	+	-1.756	+	0	+	0	+	1.1102230246252E-16
	=	0.61

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.17 Mil.

Aytu BioPharma (NAS:AYTU) Pre-Tax Income Explanation

Aytu BioPharma's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	0.608	/	22.934
	=	2.65%

During the past 13 years, Aytu BioPharma's highest Pretax Margin was -15.88%. The lowest was -10833.90%. And the median was -324.51%.

Aytu BioPharma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma (Aytu BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (NAS:AYTU) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

AY20:Germany

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

Executives

Christopher Brooke	officer: Chief Operating Officer	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Jarrett Disbrow	officer: Chief Business Officer	373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
John Jr. Donofrio	director	C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Carl Dockery	director	P.O. BOX 2477, LAKELAND FL 33806-2477
Vivian H Liu	director
Mark K Oki	officer: Chief Financial Officer	C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Joshua R. Disbrow	director, officer: Chief Executive Officer	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Abhinav Jain	director	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Greg Pyszczymuka	officer: Chief Commerical Officer	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050